Ultime notizie per Digicann Ventures (OTC:AGFAF) Azioni

Digicann Ventures Inc Formerly Agra Ventures Ltd is a pharmaceutical company engaged in the sale of cannabis-related products. The company's geographic segment includes Germany and Canada, with the majority of sales coming from Germany.

DIGICANN VENTURES INC by Digicann Ventures Inc.

Digicann Ventures Inc

Benchmark analyst Cody Acree reiterates ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

Benchmark Reiterates Hold on ARM Holdingsto Hold

Poster Presentation Reviews the Hemopurifier&#xAE; Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples
SAN DIEGO, June 9, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4444407-1&amp;h=3136272918&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Faethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOmI3YWI2N2Q2OWRiZjI1MjAzMDg1MWYzYTRmNWQ4YjYxOjY6NjNiYTpmNzBkM2E2YjIwNTc2MDI1ZjRlZmJiMWVmMzQ5Mzg2MDJmMjk4M2EwZTcwOGM5NDUyOTJiNTY1NWFlNjFlYzhhOnA6VDpO&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel &amp; Spa, Santa Fe, NM, United States, August 10-13,2025.
Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective.
Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. &nbsp;EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation.
Aethlon Medical's Hemopurifier&#xAE; is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose.
The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered &nbsp;from COVID-19 in order to examine whether&nbsp; individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively.

AEMD

Aethlon Medical Announces Poster Presentation At Keystone Symposium On Long COVID And Other Post-Acute Infection Syndromes; Presentation Reviews Hemopurifier Affinity Resin's Ability To Bind Extracellular Vesicles In Long COVID Samples

MoneyHero Collaborates With OSL Group To Expands Digital Asset Wealth Product Offerings In Hong Kong

AIRJ

AirJoule Technologies Set To Join Russell 3000 Index At Conclusion Of 2025 Russell US Indexes Annual Reconstitution, Effective June 30, 2025

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and lowers the price target from $153 to $150.

Price Target

AXSM

Needham Maintains Buy on Axsome Therapeutics, Lowers Price Target to $150

GrowGeneration Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) ("GrowGen" or the "Company"), the nation's largest specialty retailer of hydroponic and organic gardening products, today announced its acquisition of Viagrow, a domestic supplier of gardening and hydroponic equipment, in a move that expands the Company's presence in the home gardening and big box retail segments. Under the terms of the agreement, GrowGen is purchasing Viagrow, currently a $3 million annual revenue company, for cash and stock considerations.

GRWG

GrowGeneration Acquires Viagrow, Expanding Presence In Home Gardening And Big Box Retail Segments; Terms Not Disclosed

<a href="https://www.esmoopen.com/article/S2059-7029%2825%2901155-X/fulltext" title="https://www.esmoopen.com/article/S2059-7029%2825%2901155-X/fulltext">https://www.esmoopen.com/article/S2059-7029%2825%2901155-X/fulltext</a>

Guardiant Health Highlights Study Published In ESMO Open Titled 'Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer'

Seaport Global analyst Jeff Campbell upgrades Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) from Neutral to Buy and announces $71 price target.

Upgrades

OKLO

Seaport Global Upgrades Oklo to Buy, Announces $71 Price Target

Contracts

NVEE

NV5 Wins $5M High-Voltage Data Center Substation Design Services Contract

<ul>
<li>Acquisition Target Specializes in High-Precision Electrical and Mechanical Assembly, Including Printed Circuit Board Manufacturing for Commercial and Industrial Customers Across the U.S.A.</li>
<li>PMGC's second pending acquisition since April, demonstrates that its M&amp;A strategy is well underway, with additional deals expected this year.</li>
</ul>
NEWPORT BEACH, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent ("LOI") to acquire a U.S.-based, cash-flow positive electronics contract manufacturing company with over 40 years of operational history.

ELAB

PMGC Holdings Signs Non-Binding LOI To Acquire U.S.-Based, Cash-Flow Positive Electronics Contract Manufacturing Company; Terms Undisclosed

Biotech

Events

General

HUMA

Humacyte Presents Results From V007 Pivotal Phase 3 AV Access Study At Society Vor Vascular Surgery Meeting

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

Chugai Pharmaceutical Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CHGCY#OTC">CHGCY</a>) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">oral obesity pill</a>, orforglipron.
Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) is a major shareholder of Chugai, a Japanese pharmaceutical company. The company&#8217;s optimism stems from growing evidence that modern weight-loss drugs can lead to significant muscle loss, an issue Chugai thinks it can help address.
Hitoshi Iikura, a senior executive at Chugai, <a target="_blank" href="https://www.ft.com/content/4fd1fd94-0b70-48fb-861b-3bad6286ebae" rel="noreferrer noopener">told</a> the Financial Times the company has &#8220;high expectations&#8221; for combining GYM329, initially developed for spinal muscular atrophy (SMA), with orforglipron or similar therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45769020/mounjaro-maker-eli-lilly-taps-swedish-firm-camurus-to-target-long-acting-obesity-market-in-870-million-deal" rel="noreferrer noopener">Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal</a>
Orforglipron, which Lilly licensed from Chugai, showed strong late-stage trial results, matching the safety and efficacy of popular injectables like Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy and Ozempic and Lilly&#8217;s Zepbound and Mounjaro.
The drug significantly <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" rel="noreferrer noopener">reduced weight and blood sugar levels</a> and is expected to hit the market next year.
Chugai began developing orforglipron in 2003 as part of an effort to enhance diabetes treatments, aiming to make them longer-acting and tablet-based. Although obesity wasn&#8217;t an initial target, the company saw broader potential as research evolved. &#8220;We didn&#8217;t anticipate it but it&#8217;s ballooning,&#8221; Iikura said, referring to the unexpectedly large obesity market.
Studies suggest that 25% to 39% of weight loss from obesity drugs may be due to lean mass reduction, which includes muscle. Chugai argues that maintaining muscle mass is vital, especially for aging populations, and its GYM329 drug could be a key component in preventing this loss during weight-loss treatment.
Despite Chugai&#8217;s success, Roche had previously passed on orforglipron due to setbacks with an earlier weight-loss drug. At the time, much of the pharmaceutical industry was hesitant to enter the obesity space, except companies like Lilly and Novo Nordisk with strong metabolic disease portfolios.
However, with market interest and scientific breakthroughs accelerating, Roche reversed course in 2023 and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">reentered the field</a>.
Meanwhile, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-06-07/lilly-s-obesity-drug-sales-rise-60-in-india-amid-rising-demand" rel="noreferrer noopener">reported</a> that Eli Lilly saw a 60% jump in sales of its weight-loss and diabetes drug Mounjaro in India in May compared to April, marking its second full month on the Indian market.
India has the third-largest obese population in the world.
According to market research firm Pharmarack Technologies, the U.S. drugmaker made 126 million rupees ($1.5 million) from Mounjaro injections last month.
Sales of the 5 mg dose more than doubled to 75 million rupees, while the 2.5 mg version brought in 51 million rupees.
According to the Indian Council of Medical Research (ICMR), there are 101 million people with diabetes in India. Of these, at least 40 million are on medication.
Vishal Manchanda, SVP of institutional research at Systematix Group,&nbsp;told&nbsp;Livemint that even if 0.5% of 40 million use Mounjaro, it would fetch Eli Lilly sales of <a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">$1.5 billion annually</a>.
Novo Nordisk&nbsp;is also trying to move up the launch of Wegovy in India to better compete with Lilly.
Price Action: LLY stock closed up 0.55% at $769.88 on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say</a></li>
</ul>
Photo via Shutterstock

Health Care

CHGCY

RHHBY

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy

Buybacks

Viemed Healthcare Board Authorized Share Repurchase Program Up To ~1.98M Common Shares Through June 2026

Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda&#xAE;&nbsp;(pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S. Food and Drug Administration (FDA), later in June 2025
Resolution of partial clinical hold unlocks second tranche of funds from $12.5 million PIPE financing announced on June 3, 2025
TAMPA, Fla., June 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the FDA has removed the manufacturing-related partial clinical hold on the Company's Phase 3 accelerated approval trial for IFx-2.0, thereby allowing the trial to proceed as agreed to under the previously announced SPA Agreement with the FDA.

HURA

FDA Removes Manufacturing-Related Partial Clinical Hold On TuHURA's Phase 3 Accelerated Approval Trial For IFx-2.0, Allowing Trial To Proceed As Agreed To Under Previously Announced SPA Agreement With FDA

Viemed Healthcare Announces Share Repurchase Program Of 1,976,441 Shares

Legal

GPUS

Hyperscale Data Enters Into Settlement Agreement With Gresham Worldwide's Senior Secured Noteholders For Chapter 11 Proceedings

PMGC Holdings Signe Letter Of Intent To Acquire Profitable U.S.-Based Electronics Manufacturing Company

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe
Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET
PRINCETON, N.J., June 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it will host a virtual key opinion leader (KOL) event featuring Kevin Harrington, MBBS, PhD (The Institute of Cancer Research, United Kingdom) and Katharine A. Price, MD (Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center), to discuss the unmet need and current treatment landscape for recurrent/metastatic HPV16-positive (head and neck squamous cell carcinoma) HNSCC.
The event will review the changing landscape of HNSCC in context with Merck's KEYNOTE-689 (KN-689) study and the rapidly increasing incidences of HPV16-positive HNSCC in the US and Europe. The event will also include a review of Versamune&#xAE; HPV, which is currently being evaluated in a Phase 3 clinical trial in combination with pembrolizumab as a first-line treatment for R/M HPV16+ HNSCC, as well as in Phase 2 clinical trials for the treatment of various types of HPV16-positive cancers. Versamune&#xAE; HPV is a novel investigational human papilloma virus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. The panel will discuss the emerging treatment landscape in 1L R/M HNSCC and the view of HPV-positive and HPV-negative HNSCC as two distinct diseases with different underlying causes, pathology, and contributions to the development of HNSCC, as well as identification and treatment of HPV16+ HNSCC.
The event will be moderated by Kirk Shepard, M.D., PDS Biotech's Chief Medical Officer. A live question and answer session will follow the formal presentations.

PDSB

PDS Biotechnology To Host Virtual KO) Event To Discuss Unmet Need And Current Treatment Landscape For Recurrent/Metastatic HPV16-Positive HNSCC

<h3>Gainers</h3>
<ul>
<li>EpicQuest Education Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) stock rose 12.8% to $0.61 during Monday's pre-market session. The market value of their outstanding shares is at $8.0 million. </li>
<li>VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) shares rose 11.69% to $3.82. The company's market cap stands at $8.9 billion. As per the news, the Q1 earnings report came out today. </li>
<li>PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) shares moved upwards by 10.04% to $1.75. The company's market cap stands at $164.3 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares increased by 9.99% to $2.75. The market value of their outstanding shares is at $6.9 million. </li>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares increased by 9.2% to $1.78. The market value of their outstanding shares is at $189.6 million. </li>
<li>JX Luxventure Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) stock moved upwards by 8.57% to $2.66. The company's market cap stands at $10.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) shares decreased by 21.1% to $5.41 during Monday's pre-market session. The market value of their outstanding shares is at $119.2 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) stock declined by 7.63% to $0.47. The market value of their outstanding shares is at $5.4 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock fell 6.54% to $2.29. The company's market cap stands at $7.0 million. </li>
<li>Linkage Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares fell 6.23% to $2.26. The market value of their outstanding shares is at $5.8 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock declined by 5.98% to $39.0. The market value of their outstanding shares is at $27.2 million. </li>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) stock fell 5.3% to $1.79. The market value of their outstanding shares is at $4.2 million. As per the press release, Q1 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CHGG

EEIQ

LGCB

PLBY

PLCE

RIME

SBET

SPHL

XELB

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

Press Releases

Digicann Ventures and 3Win Corp. Sign Binding LOI for Proposed RTO Transaction

Digicann Ventures Signs Definitive Agreement for Proposed RTO Transaction with 3Win Corp.

Digicann Ventures Announces Agreement to Extend Maturity Date for Convertible Debentures

Comments

Digicann Ventures

Notizie

Ultime notizie per Digicann Ventures (OTC:AGFAF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO